Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: Results of a modified prescription-event monitoring study

Drug Safety

Volumn 36, Issue 4, 2013, Pages 237-246

  Davies, Miranda ^a,b   Wilton, Lynda ^a,b   Shakir, Saad ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; MODAFINIL;

ABDOMINAL PAIN; AGITATION; ANXIETY DISORDER; CHRONIC FATIGUE SYNDROME; COHORT ANALYSIS; DEMOGRAPHY; DERMATITIS; DIARRHEA; DIZZINESS; DREAMING; DROWSINESS; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUPHORIA; GOUT; HEADACHE; HEART FAILURE; HEART PALPITATION; HUMAN; HYPERACTIVITY; HYPERTENSION; INSOMNIA; LASSITUDE; MALAISE; MODIFIED PRESCRIPTION EVENT MONITORING; MULTIPLE SCLEROSIS; NARCOLEPSY; NATIONAL HEALTH SERVICE; NAUSEA; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; PARKINSON DISEASE; PATIENT INFORMATION; PHYSICIAN; PREGNANCY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SLEEP DISORDERED BREATHING; THORAX PAIN; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VISUAL DISORDER; VOMITING; WAKEFULNESS;

ADOLESCENT; ADULT; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COHORT STUDIES; DRUG PRESCRIPTIONS; ENGLAND; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOLEPSY; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; PRODUCT SURVEILLANCE, POSTMARKETING; QUESTIONNAIRES; SLEEP DISORDERS; YOUNG ADULT;

EID: 84876705288     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0025-y     Document Type: Review

References (18)

1. European Medicines Agency (EMA). Assessment report for modafinil containing medicinal products. London: EMA; 2011.
2. Cephalon Inc. Dear Healthcare Professional letter. Updated safety information: warnings regarding serious rash, including Stevens-Johnson Syndrome and hypersensitivity reactions, and psychiatric symptoms. Silver Spring: US FDA. 2007. http://www.fda.gov/medwatch/safety/2007/Provigil-dhcpletter091207- final.pdf. Accessed May 2012.
3. ®. Castleford: Cephalon UK Limited; 2012.
4. Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work. Am J Psychiatry. 2005;162(10):1983.
5. Ranjan S, Chandra PS. Modafinil-induced irritability and aggression? A report of 2 bipolar patients. J Clin Psychopharmacol. 2005;25(6):628-9.
6. Vorspan F, Warot D, Consoli A, Cohen D, Mazet P. Mania in a boy treated with modafinil for narcolepsy. Am J Psychiatry. 2005;162(4):813-4.
7. Kruszewski SP. Euphorigenic and abusive properties of modafinil. Am J Psychiatry. 2006;163(3):549.
8. Oskooilar N. A case of premature ventricular contractions with modafinil. Am J Psychiatry. 2005;162(10):1983-4.
9. Boellner SW, Earl CQ, Arora S. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study. Curr Med Res Opin. 2006;22(12):2457-65.
10. Lindsay SE, Gudelsky GA, Heaton PC. Use of modafinil for the treatment of attention deficit/hyperactivity disorder. Ann Pharmacother. 2006;40(10):1829-33.
11. Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006;67(1):137-47.
12. Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med. 2003;4(6):579-82.
13. Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. Drug Saf. 2011;34(12):e1-9.
14. Shakir S. Causality and correlation in pharmacovigilance. In: Talbot J, Waller P, editors. Stephens' detection of new adverse drug reactions. 5th ed. Chichester: Wiley; 2004. p. 329-43.
15. CIOMS, WHO. International ethical guidelines for biomedical research involving human subjects. Geneva: Switzerland. 2002. http://www.cioms.ch/ publications/guidelines/guidelines-nov-2002-blurb.htm. Accessed May 2012.
16. Drug Safety Update. Monthly newsletter from MHRA. Vol 1. Issue 8, March 2008.
17. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol. 1998; 43(1):88-97.
18. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000; 54(5):1166-5.